P
Philipp Angenendt
Researcher at Johns Hopkins University
Publications - 18
Citations - 10411
Philipp Angenendt is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: KRAS & Cancer. The author has an hindex of 9, co-authored 18 publications receiving 9621 citations. Previous affiliations of Philipp Angenendt include Sysmex Corporation & Howard Hughes Medical Institute.
Papers
More filters
Journal ArticleDOI
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
D. Williams Parsons,Siân Jones,Xiaosong Zhang,Jimmy Lin,Rebecca J. Leary,Philipp Angenendt,Parminder Mankoo,Hannah Carter,I-Mei Siu,Gary L. Gallia,Alessandro Olivi,Roger E. McLendon,B.K. Ahmed Rasheed,Stephen T. Keir,Tatiana Nikolskaya,Yuri Nikolsky,Dana A. Busam,Hanna Tekleab,Luis A. Diaz,James Hartigan,Doug R. Smith,Robert L. Strausberg,Suely Kazue Nagahashi Marie,Sueli Mieko Oba Shinjo,Hai Yan,Gregory J. Riggins,Darell D. Bigner,Rachel Karchin,Nick Papadopoulos,Giovanni Parmigiani,Bert Vogelstein,Victor E. Velculescu,Kenneth W. Kinzler +32 more
TL;DR: Recurrent mutations in the active site of isocitrate dehydrogenase 1 (IDH1) occurred in a large fraction of young patients and in most patients with secondary GBMs and were associated with an increase in overall survival.
Journal ArticleDOI
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Siân Jones,Xiaosong Zhang,D. Williams Parsons,D. Williams Parsons,Jimmy Lin,Rebecca J. Leary,Philipp Angenendt,Parminder Mankoo,Hannah Carter,Hirohiko Kamiyama,Antonio Jimeno,Seung-Mo Hong,Baojin Fu,Ming Tseh Lin,Eric S. Calhoun,Mihoko Kamiyama,Kimberly Walter,Tatiana Nikolskaya,Yuri Nikolsky,James Hartigan,Douglas Smith,Manuel Hidalgo,Steven D. Leach,Alison P. Klein,Elizabeth M. Jaffee,Michael Goggins,Anirban Maitra,Anirban Maitra,Christine A. Iacobuzio-Donahue,James R. Eshleman,Scott E. Kern,Ralph H. Hruban,Rachel Karchin,Nickolas Papadopoulos,Giovanni Parmigiani,Bert Vogelstein,Victor E. Velculescu,Kenneth W. Kinzler +37 more
TL;DR: It is found that pancreatic cancers contain an average of 63 genetic alterations, the majority of which are point mutations, which defined a core set of 12 cellular signaling pathways and processes that were each genetically altered in 67 to 100% of the tumors.
Journal ArticleDOI
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells.
Jihye Yun,Carlo Rago,Ian Cheong,Ray Pagliarini,Ray Pagliarini,Philipp Angenendt,Harith Rajagopalan,Harith Rajagopalan,Kerstin Schmidt,James K V Willson,Sandy D. Markowitz,Shibin Zhou,Luis A. Diaz,Victor E. Velculescu,Christoph Lengauer,Christoph Lengauer,Kenneth W. Kinzler,Bert Vogelstein,Nickolas Papadopoulos +18 more
TL;DR: Studying the transcriptomes of paired colorectal cancer cell lines that differed only in the mutational status of their KRAS or BRAF genes, it is suggested that glucose deprivation can drive the acquisition of KRAS pathway mutations in human tumors.
Journal ArticleDOI
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
Maria Pia Morelli,Michael J. Overman,Arvind Dasari,Syed Mohammad Ali Kazmi,Thibault Mazard,Eduardo Vilar,Van K. Morris,M. S. Lee,Delise H. Herron,Cathy Eng,J. Morris,Bryan K. Kee,Filip Janku,F. L. Deaton,Christopher R. Garrett,Dipen M. Maru,Frank Diehl,Philipp Angenendt,Scott Kopetz +18 more
TL;DR: Multiple simultaneous mutations in KRAS and EGFR in the ctDNA and the decline in allele frequency after discontinuation of anti-EGFR therapy in a subset of patients suggest that several resistance mechanisms can co-exist and that relative clonal burdens may change over time.
Journal ArticleDOI
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)
Chris Karlovich,Jonathan H. Goldman,Jong-Mu Sun,Elaina Mann,Lecia V. Sequist,Krzysztof Konopa,Wei Wen,Philipp Angenendt,Leora Horn,David R. Spigel,Jean-Charles Soria,Benjamin Solomon,D. Ross Camidge,Shirish M. Gadgeel,Cloud P. Paweletz,Lin Wu,Sean Chien,Patrick O'Donnell,Shannon Matheny,Darrin Despain,Lindsey Rolfe,Mitch Raponi,Andrew R. Allen,Keunchil Park,Heather A. Wakelee +24 more
TL;DR: The findings suggest the cobas and BEAMing plasma tests can be useful tools for noninvasive assessment and monitoring of the T790M resistance mutation in NSCLC, and could complement tumor testing by identifying T790m mutations missed because of tumor heterogeneity or biopsy inadequacy.